Credit Suisse Group initiated coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research report report published on Tuesday, TipRanks reports. The brokerage issued a buy rating and a $142.00 price objective on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on the company. Wolfe Research began coverage on Alexion Pharmaceuticals in a research report on Thursday, March 12th. They set an outperform rating and a $140.00 price objective for the company. Cantor Fitzgerald began coverage on Alexion Pharmaceuticals in a research report on Monday, April 27th. They set a neutral rating and a $121.00 price objective for the company. SunTrust Banks lowered their price target on Alexion Pharmaceuticals from $141.00 to $135.00 and set a buy rating for the company in a research report on Friday, May 8th. Bank of America lowered Alexion Pharmaceuticals from a buy rating to a neutral rating and lowered their price target for the stock from $130.00 to $110.00 in a research report on Thursday, March 5th. Finally, BidaskClub raised Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, March 19th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of Buy and an average price target of $141.91.
Shares of NASDAQ ALXN opened at $114.42 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.35 and a quick ratio of 3.82. Alexion Pharmaceuticals has a one year low of $72.67 and a one year high of $134.84. The stock has a market capitalization of $23.44 billion, a P/E ratio of 10.77, a PEG ratio of 0.83 and a beta of 1.41. The firm’s 50 day simple moving average is $101.87 and its two-hundred day simple moving average is $102.40.
In other news, Director Bros. Advisors Lp Baker purchased 265,298 shares of the business’s stock in a transaction on Monday, March 16th. The stock was acquired at an average cost of $78.76 per share, for a total transaction of $20,894,870.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 4.03% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the business. State of Tennessee Treasury Department grew its stake in shares of Alexion Pharmaceuticals by 110.1% during the 1st quarter. State of Tennessee Treasury Department now owns 352,028 shares of the biopharmaceutical company’s stock valued at $31,609,000 after purchasing an additional 184,453 shares during the period. Tredje AP fonden grew its stake in shares of Alexion Pharmaceuticals by 6.6% during the 1st quarter. Tredje AP fonden now owns 43,326 shares of the biopharmaceutical company’s stock valued at $3,890,000 after purchasing an additional 2,693 shares during the period. National Pension Service grew its stake in shares of Alexion Pharmaceuticals by 2.1% during the 1st quarter. National Pension Service now owns 366,942 shares of the biopharmaceutical company’s stock valued at $32,948,000 after acquiring an additional 7,392 shares during the period. 1832 Asset Management L.P. bought a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at approximately $29,753,000. Finally, Verus Capital Partners LLC grew its stake in shares of Alexion Pharmaceuticals by 560.0% during the 1st quarter. Verus Capital Partners LLC now owns 660 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 560 shares during the period. Institutional investors and hedge funds own 88.80% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: How a Put Option Works
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.